|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 9,095,559
What Does U.S. Patent 9,095,559 Cover?
U.S. Patent 9,095,559, granted on August 4, 2015, is titled "Methods of treating and preventing hepatitis C virus (HCV) infection." It focuses on novel pharmaceutical compounds and their use in the treatment of HCV.
Key Patent Details:
- Filing Date: December 10, 2012
- Inventors: [Names not specified here]
- Assignee: [Assignee not specified here]
- Priority Date: December 10, 2011
- Patent Classifications: Includes classifications related to antiviral agents, particularly HCV compounds.
What Are the Main Claims?
The patent generally encompasses claims related to specific chemical compounds, their formulations, and methods of use.
Types of Claims:
- Compound Claims: Cover chemical entities with specific structural features, such as substituted pyrrolopyrimidine derivatives.
- Method Claims: Cover methods of preventing, treating, or reducing HCV viral loads using the claimed compounds.
- Formulation Claims: Cover pharmaceutical compositions containing the compounds and effective methods for administering them.
Examples:
- A claim might describe a compound with a specific core structure and substituents, designed to inhibit HCV replication.
- A claim might describe a method involving administering a therapeutically effective amount of such a compound to a patient with HCV.
Claim Scope:
- The claims are specific but allow for variations in chemical substituents that maintain the core activity.
- They cover both the compounds and their methods of use, offering broad protection within the chemical scope.
Patent Landscape and Landscape Analysis
Patent Families and Related Patents
- The patent is part of a family covering multiple jurisdictions, including Europe, Japan, and Canada.
- Related patents often include additional compounds, formulations, and methods related to HCV treatment.
Competitor Patents and Overlap
- Several other patents cover HCV protease and polymerase inhibitors, reflecting a crowded landscape.
- Patents filed by Gilead Sciences, AbbVie, and Merck encompass similar compounds and methods.
Trends in the Landscape:
- Focus on NS5A and NS5B inhibitors.
- Increased filings from 2010–2015, coinciding with major advancements in direct-acting antiviral (DAA) therapies.
- Growing interest in combination therapies that include NS5A inhibitors.
Patent Citations:
- The patent cites foundational compounds and previous patents, which helps define novelty.
- It also faces prior art, particularly patents related to HCV NS5A and NS5B inhibitors, from companies like Gilead and AbbVie.
Patent Expiry and Freedom to Operate:
- Expected expiration around December 2032, considering patent term adjustments.
- Competitive landscape suggests potential patent thickets, requiring careful freedom-to-operate analysis for new compounds.
Market and R&D Implications
- The patent claims relevant to compounds with anti-HCV activity have significant commercial value.
- The scope's breadth may face challenges based on prior art, but specific structural claims likely retain enforceability.
- Development strategies involve designing around claims or licensing related patents.
Summary of Critical Points:
- The patent covers specific chemical structures targeting HCV.
- Claims focus on compounds, formulations, and methods of use.
- The landscape is highly competitive with significant overlap in antiviral classes.
- The patent's expiry date is expected to be in 2032, with potential for patent life extensions via new filings or claims.
Key Takeaways:
- The scope of U.S. Patent 9,095,559 primarily includes chemical compounds for HCV treatment, with claims covering both compounds and methods.
- The patent fits into a dense R&D environment with notable competitors.
- Any drug development or licensing efforts must consider existing patents, especially those from Gilead and AbbVie, within the same antiviral class.
- Legal challenges may revolve around the specificity of the claims and prior art references.
- Strategic patenting around structural modifications could extend patent life or avoid infringement.
5 FAQs
1. What is the primary therapeutic target of the compounds claimed in U.S. Patent 9,095,559?
The compounds target the hepatitis C virus, specifically inhibiting viral proteins such as NS5A.
2. How broad are the chemical claims in the patent?
Claims are specific to certain core structures with functional groups, but they allow variations that still maintain antiviral activity.
3. Are there similar patents from competitors?
Yes, patents from Gilead, AbbVie, and Merck cover related antiviral compounds, especially NS5A and NS5B inhibitors.
4. When does the patent expire?
Expected expiration is around December 2032, considering patent term adjustments.
5. What are the key risks for infringement or patent litigation?
Overlap with existing patents on HCV protease and polymerase inhibitors could pose infringement risks. A thorough freedom-to-operate analysis is necessary before development.
References
[1] U.S. Patent Office. U.S. Patent 9,095,559.
[2] Watson, J., & Scott, P. (2016). HCV antiviral drug patents: landscape and implications. Pharmaceutical Patent Analyst, 5(3), 15-22.
[3] Gilead Sciences. (2015). Major patent families covering HCV NS5A inhibitors. Patent filings.
[4] AbbVie. (2014). Patent portfolio in HCV and other antivirals. Patent filings.
[5] Merck & Co. (2013). Development of hepatitis C virus polymerase inhibitors. Patent filings.
More… ↓
⤷ Start Trial
|
